About Us       Blog       Clients       Disclaimer       Market Basics       Partners       Quotes & News       Video       Contact Us
The QualityStocks Daily Newsletter for Thursday, September 7th, 2017

The QualityStocks
Daily Stock List


CIB Marine Bancshares, Inc. (CIBH)

MarketWatch and Stock Traders Chat reported on CIB Marine Bancshares, Inc. (CIBH), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.

CIB Marine Bancshares, Inc. operates as the bank holding company for CIBM Bank. The Bank provides banking and related services for small and middle-market business customers. CIB Marine Bancshares has its corporate headquarters in Waukesha, Wisconsin. The Bank also has offices in the Central and Northeastern Illinois, Milwaukee, as well as Indianapolis markets. Incorporated in 1985, CIB Marine Bancshares’ shares trade on the OTC Markets.

CIBM Bank operates as Marine Bank in its Indiana and Wisconsin markets, Central Illinois Bank in its central Illinois market, and Avenue Bank in its Chicagoland market. Situated in Naperville, Illinois, the Avenue Mortgage division of the Bank serves all CIBM Bank markets.

The Company operates by way of Banking and Mortgage Banking segments. It accepts demand, savings, and also time deposits. 

The traditional banking services that CIBM Bank provides include a wide spectrum of loan products. These include commercial loans, commercial real estate loans, commercial and residential construction loans, one-to-four family residential real estate loans, consumer loans, and commercial and standby letters of credit. In addition, services provided include acceptance of demand, savings and time deposits; commercial paper and repurchase agreements, and other banking services.

Recently, CIB Marine Bancshares announced its results of operations and financial condition for Q2 of 2017. Net Income for Q2 was $1.0 million, or $0.06 basic earnings per share and $0.03 diluted earnings per share. For the six months ending June 30, 2017, Net Income was $1.9 million, or $0.11 basic and $0.05 diluted earnings per share.

Mr. J. Brian Chaffin, President and Chief Executive Officer of CIB Marine, said, "CIB Marine's second quarter improvement over the first quarter of 2017 reflects the higher level of earning assets and improved quality of our non-interest income with more coming from our core business activities as opposed to collection activities. Thirteen of the last fourteen quarters have been profitable at CIBM Bank, and this marks the sixth consecutive quarter of profits.”

CIB Marine Bancshares, Inc. (CIBH), closed Thursday's trading session at $1.39, down 0.71%, on 2,752 volume with 3 trades. The average volume for the last 60 days is 5,266 and the stock's 52-week low/high is $0.91/$1.55.

Galaxy Gaming, Inc. (GLXZ)

SmallCapVoice, TaglichBrothers, Marketbeat, RedChip, The Green Baron, FeedBlitz, and Stock Profile reported previously on Galaxy Gaming, Inc. (GLXZ), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.

Galaxy Gaming, Inc. is the world's largest independent developer, manufacturer, and distributor of casino table games and enhanced systems. The Company develops, manufactures, and distributes unique proprietary table games, state-of-the-art electronic wagering platforms, and enhanced bonusing systems to land-based, riverboat, cruise ships, and online casinos internationally. Galaxy Gaming is headquartered in Las Vegas, Nevada.

The Company has an installed base of its products on thousands of gaming tables located in hundreds of casinos. Galaxy Gaming sells its products primarily through its internal sales force, to casinos across North America, the Caribbean, the British Isles, Europe, and Africa, as well as to cruise ships and internet gaming sites globally.  

By way of its iGaming partner, Games Marketing Ltd., Galaxy Gaming licenses its proprietary table games to the online gaming industry. The Company’s games can be played online at FeelTheRush.com. 

In addition, Galaxy Gaming is expanding its worldwide footprint through its partnership with WPT Enterprises, Inc.  WPT Enterprises is the owner of the World Poker Tour.

Moreover, Galaxy Gaming is the exclusive provider of SpectrumVision. This is a proprietary technology utilized to detect invisible markings on playing cards.

In late July, Galaxy Gaming announced that Mr. Todd P. Cravens, its Vice President of Business Development, succeeded Galaxy’s Founder, Mr. Robert B. Saucier, as President and Chief Executive Officer (CEO).  Mr. Saucier remains with Galaxy Gaming as a Director. He has been appointed to the position of Executive Vice President of Business Development and Chief Product Officer.

Before joining Galaxy Gaming in January of this year, Mr. Cravens was the CEO of the Americas for TCS John Huxley. He has greater than 25 years of experience in the gaming and entertainment industries.

In August, Galaxy Gaming announced its results for the quarter ended June 30, 2017. The Company had Revenue of $3,659K, which represents an increase of 19 percent. It had Adjusted EBITDA (Earnings Before Interest, Taxes Depreciation, and Amortization) of $1,110K, which represents a decrease of 15 percent. The Company had a Net Loss of $80K in comparison to Net Income of $563K.

Mr. Todd Cravens, Galaxy Gaming’s newly-appointed Chief Executive Officer, said in August, “Our year-over-year revenue growth of 19.4 percent was very strong. Consistent with statements made in our Q1 2017 earnings press release, near-term investments in our sales, marketing and compliance resources are negatively affecting affect our profits.  However, we continue to believe that those investments are necessary to position us for sustained growth over the long-term.”

Galaxy Gaming, Inc. (GLXZ), closed Thursday's trading session at $0.7584, up 2.49%, on 500 volume with 1 trade. The average volume for the last 60 days is 11,161 and the stock's 52-week low/high is $0.37/$0.82.

Synergy CHC Corp. (SNYR)

SmallCapVoice, MarketWatch, OTC Markets, and TradingView reported earlier on Synergy CHC Corp. (SNYR), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Synergy CHC Corp. is a consumer health care company listed on the OTC Markets. It is in the process of building a portfolio of best-in-class consumer product brands. The Company’s strategy is to increase its portfolio organically and through further acquisition. Established in 2012, Synergy CHC is headquartered in Westbrook, Maine. 

The Company sells its products mainly in North American retail locations. Its diversified portfolio includes Flat Tummy Tea™, FOCUSFactor™, Neuragen™, and Hand MD®. Flat Tummy Tea™ is an innovatively formulated two-step herbal detox tea. It works to naturally help speed up metabolism, boost energy, and reduce bloating to flatten one’s stomach/tummy. 

FOCUSFactor is a nutritional supplement. It includes a proprietary blend of brain supporting vitamins, minerals, antioxidants, and other nutrients. 

Neuragen® is a topical product. It works directly at the site of the pain contrasted with oral products. Neuragen® reduces the spontaneous firing of damaged peripheral nerves.

Also, Synergy CHC’s Hand MD® is the world's first anti-aging skincare line formulated specifically for the hands. Synergy CHC has also launched its newest brand, Sneaky Vaunt®

Synergy CHC officially launched The Synergy Effect, its ROI (Return on Investment) innovation engine and online marketing platform. The Synergy Effect was built to boost online revenue growth for all of the Company’s brands.

This past June, Synergy CHC announced that it entered into, and at the same time closed on, an Asset Purchase Agreement with Per-fekt Beauty Holdings, LLC and CDG Holdings, LLC, which owns 92.3 percent of the issued and outstanding equity interests of Per-fekt Beauty. Per-fekt Beauty engages in developing and selling skincare and cosmetics products under the brand Per-fekt.

With this Purchase Agreement, Synergy CHC purchased all of Per-fekt Beauty's assets and assumed certain of its liabilities for a purchase price of $709,988.34. As additional consideration, it will pay quarterly royalties equal to 5 percent of Net Sales for 10 years following the closing date.

Last month, Synergy CHC reported results for the quarter ended June 30, 2017. Net Sales were $9.3 million, versus $8.2 million for the same quarter in 2016. This represents a 13 percent increase. For Q2, Net Loss was $0.05 million or $0.00 (basic and diluted) earnings per share, versus a Net Loss of $0.01 million or $0.00 (basic and diluted) earnings per share for 2016. 

Net Sales for the six months ended June 30, 2017 were $20.1 million, versus $16.5 million for the same period in 2016. This represents a 22 percent increase. For the six months ended June 30, 2017, Net Income was $2.5 million, or $0.03 (basic and diluted) earnings per share, versus Net Income of $2.8 million or $0.03 (basic and diluted) earnings per share for the same period in 2016.

During the six months of 2017, the Company reduced its debt to $3.6 million from $7.6 million. This represents a 53 percent decrease.

Synergy CHC Corp. (SNYR), closed Thursday's trading session at $0.52, down 1.89%, on 38,283 volume with 11 trades. The average volume for the last 60 days is 51,049 and the stock's 52-week low/high is $0.20/$0.80.

Destiny Media Technologies, Inc. (DSNY)

Bullseyestox, Stockhouse, Wall Street Resources, Greenbackers, SmallCapVoice, Blaque Capital Stocks, Breaking Bulls, and OTC Picks reported earlier on Destiny Media Technologies, Inc. (DSNY), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Destiny Media Technologies, Inc. provides services that enable content owners to securely display and distribute their audio and video content digitally by way of the internet. The OTCQB-listed Company’s two major services are Clipstream® and Play MPE®. It has granted patents for secure distribution and watermarking and a pending patent for cross platform PC and mobile streaming. Destiny Media Technologies is headquartered in Vancouver, British Columbia.

Clipstream® is a video format, which plays on any modern smart phone, tablet, internet, TV, or computer. Play MPE® provides a standardized method to securely and cost effectively distribute pre-release music to radio stations and other music industry professionals, before it is ready for sale.

Destiny Media Technologies’ revenue and earnings growth has been boosted by the flagship Play MPE® system. Currently, it produces about 99 percent of the Company’s revenue. The Play MPE® system is being embraced by the music industry as the standard for securely moving their pre-release music to radio stations and other recipients.

Destiny Media Technologies has launched the next generation of the player used in the Clipstream® hosting and reporting service. This version contains the first approach in the industry employing the graphics processing unit of different devices to enhance the presentation of video within the browser using a browser technology named WebGL. 

This new player can access resources unavailable to conventional technologies to upscale and enhance the video, improving the viewer experience. Initially designed for use in 3D rendering and game development, WebGL is a low-level 3D graphics API.  It gives the Clipstream player access to strong additional resources for enhancing and presenting video. Furthermore, the new player includes a number of other fixes and performance enhancements.

In late June 2017, Destiny Media Technologies reported that the Company’s Board of Directors appointed Mr. Fred Vandenberg to the role of President and Chief Executive Officer (CEO) to replace Mr. Steve Vestergaard.  Mr. Vandenberg is Destiny's Chief Financial Officer (CFO) and will remain in that role on a temporary basis. Moreover, Destiny also announced that Hyonmyong (Hoch) Cho replaced Mr. Vestergaard as Chairman of the Board of Directors.

Receently, Destiny Media Technologies announced its financial results for its fiscal 2017 Q3 ended May 31, 2017. Revenue for the quarter ended May 31, 2017 grew by 3 percent to $897,475. This was the sixth consecutive Quarter over Quarter revenue growth.

The Company’s Net Income grew to $166,223. Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) grew to more than $200,000.

Destiny Media Technologies, Inc. (DSNY), closed Thursday's trading session at $0.195, up 5.41%, on 32,125 volume with 7 trades. The average volume for the last 60 days is 12,392 and the stock's 52-week low/high is $0.13/$0.28.

Atacama Resources International, Inc. (ACRL)

OTC Markets and MarketWatch reported on Atacama Resources International, Inc. (ACRL), and we report on the Company as well, here at the QualityStocks Daily Newsletter.

Atacama Resources International, Inc. has significant mining claims in the greater Kirkland Lake area of Northern Ontario. Metals and minerals under potential exploration include gold, silver, diamonds, graphite and cobalt. Additionally, major deposits of copper and iron ore are included in the mining claims. Atacama Resources International is based in Plantation, Florida.

Concerning Minerals, Atacama Resources International has manifold claims on 4460 acres in the Kirkland Lake and other areas of mineral-rich northern Ontario. The Company’s initial line of business is a combination of mining, acquisition, and development of mining interests in the Kirkland Lake area. 

The Company is also involved in a new line of business, which it says will make the highways of the United States and Canada safer and saves lives in the process. Atacama Resources International, as part of its expansion portfolio, has acquired Good2Drive™, Inc. Good2Drive, Inc. is a wholly-owned subsidiary of Atacama Resources International. 

Good2Drive™ is an entity that has the rights to an application (app) that detects levels of cognitive awareness and reports those levels in accordance with the users' demands and requirements. The Company’s technology business includes the unique Smartphone application Good2Drive and also follow on products that will be released later this year and in 2018.

Atacama Resources International announced in April of this year that it released Good2Drive, the mobile application that enables drivers, corporate fleets, and law enforcement to test a driver's cognitive alertness before getting behind the wheel of a motor vehicle. Good2Drive utilizes a 60-90 second image matching test employing a patented algorithm, which was created based on the scientific study of cognitive abilities at various West Coast hospitals and universities. 

Good2Drive’s commitment is to providing Smartphone hosted applications based on its proprietary testing for cognitive awareness. Its set of Smartphone hosted app's will include cognitive tests for care givers, seniors with impairments, remote employees in potentially hazardous environments, and other situations where it is necessary to be cognitively alert.

Atacama Resources International has released a test version of Good2Drive Fleet. Good2Drive Fleet includes the Good2Drive test released in July. Furthermore, it adds a vital 'Results Dashboard' for fleet operators. This provides a strong new safety tool to support realistic management of hundreds or even thousands of drivers in their fleets.

Today, Atacama Resources International announced that it engaged Canadian Exploration Services Ltd. (CXS) to conduct a geological evaluation of the Company’s Cabo property. The Cabo property consists of Mining Claim 4225513, positioned in the Township of Lorrain in the heart of all the high-profile cobalt activity surrounding the historic mining town of Cobalt, Ontario.

Mr. Glenn Grant, Atacama Resources International’s Chief Executive Officer, said, "I am very excited to have a firm with the credibility and credentials of CXS to be handling this next stage of exploration on the Cabo Property. It is right in the middle of all the recent mining exploration activity being conducted for cobalt, so we are eager for this report to be completed. The Cabo property was previously mined for silver, and we believe that cobalt was also prevalent at that time.”

Atacama Resources International, Inc. (ACRL), closed Thursday's trading session at $0.00907, down 4.53%, on 938,518 volume with 34 trades. The average volume for the last 60 days is 2,152,069 and the stock's 52-week low/high is $0.0091/$0.52.


The QualityStocks
Company Corner


InMed Pharmaceuticals, Inc. (CSE:IN) (OTCQB:IMLFF)

The QualityStocks Daily Newsletter would like to spotlight InMed Pharmaceuticals, Inc. (IMLFF). Today, InMed Pharmaceuticals, Inc. closed trading at $0.26135, up 11.21%, on 497,343 volume with 183 trades. The stock’s average daily volume over the past 60 days is 254,035, and its 52-week low/high is $0.062/$0.72.

CFN Media Group ("CannabisFN"), the leading creative agency and media network dedicated to legal cannabis, announces publication of an article examining InMed Pharmaceuticals' (CSE: IN) (CNSX: IN) (IN.CN) (OTCQB: IMLFF) biosynthesis program and how it could address many vexing issues with cannabis drug development. The medical marijuana movement has made tremendous progress across the United States, but acceptance in the medical community is an entirely different story. While the FDA has approved a handful of drugs containing synthetic cannabinoids, the agency has never approved a product derived from botanical marijuana. Critics argue that synthetic cannabinoids miss the so-called entourage effect, while supporters argue that botanical marijuana isn't standardized.

InMed Pharmaceuticals, Inc. (IMLFF) is a preclinical-stage biopharmaceutical company specializing in the development of novel therapeutics leveraging the pharmacological benefits of cannabinoids. Utilizing its proprietary bioinformatics assessment tool, InMed aims to identify bioactive compounds found within the cannabis plant that have the potential to offer optimized therapeutic benefit while demonstrating limited adverse effects. This assessment tool, in combination with the company’s cannabinoid biosynthesis technology and drug development pipeline, serves as InMed’s fundamental value driver.

Bioinformatics is a proprietary, computer-based program designed to assist in the identification of novel cannabinoids using comprehensive algorithms to integrate data from numerous bioinformatics databases, as well as a database on the structure of currently approved pharmaceutical products and an extensive database on over 90 individual cannabinoid drugs found in cannabis. This extensive collection of data is derived from both public and propriety-based sources. Leveraging this tool, the company aims to create associations between approved pharmaceuticals and cannabinoids with similar structures in order to identify active cannabinoids that have the potential to treat specific diseases. Per InMed’s website, this type of bioinformatics assessment represents “significant promise for future drug discovery, as it integrates many data sets and builds holistic models to approach a specific disease.”

After discovering these promising active cannabinoids, InMed moves to test and confirm their activity in biological systems through in vitro and in vivo experimentation. It is at this stage of development that the company’s proprietary biosynthesis process of cannabinoid manufacturing will be most promising. InMed is currently developing a robust, high-yield biosynthesis process for manufacturing all 90+ naturally-occurring cannabinoids. By modifying the agriculture-based formula for harvesting cannabinoids, InMed aims to combine the inherent safety and known efficacy of the natural drug structure with the convenience, control and quality of 21st Century laboratory-based manufacturing processes.

The company’s pipeline currently includes two drug candidates in preclinical development, including INM-750 for the treatment of epidermolysis bullosa (EB) and INM-085 for the treatment of glaucoma. Referred to by the Dystrophic Epidermolysis Bullosa Research Association of America as “The Worst Disease You’ve Never Heard Of,” EB is a rare genetic connective tissue disorder that affects roughly one out of every 20,000 births in the United States. The condition currently has no approved treatment or cure. Through the development of INM-750, InMed is attempting to address this significant unmet medical need. The drug candidate replaces missing keratins in the skin with specially selected cannabinoids in an effort to modulate the painful manifestations of EB.

INM-085, InMed’s second development candidate, is formulated to reduce the elevated intra-ocular pressure that is often associated with glaucoma. Additionally, the cannabinoids utilized in INM-085 are expected to provide neuroprotection for the retinal ganglion cells and other optic nerve tissues following topical administration. Although it is still in preclinical development, INM-085 targets a sizable market. According to the Glaucoma Research Foundation, glaucoma is a leading cause of blindness with no approved cure. The National Institutes of Health estimates that more than 3 million Americans currently have glaucoma, and more than 120,000 have been blinded by the disease.

InMed is focused on progressing toward validation of its drug candidate selection, using data to secure its patents and developing key disruptive technologies. In 2016, the company was successful in completing financings of $1.9 million. In January 2017, InMed completed a non-brokered private placement of common shares generating aggregate gross proceeds of C$1.5 million, strongly positioning the company to attract the new investment required to fund its aggressive growth strategies in 2017.

The company’s management team has well over a century of combined experience in the biopharmaceutical space. Company CEO Eric Adams has more than 25 years of experience in company and capital formation, global market development, mergers and acquisitions, licensing and corporate governance. During his time as CEO of enGene Inc., he led the gene therapy startup to a position at the head of the industry.

Joining Adams on the InMed management team are Chief Scientific Officer Dr. Sazzan Hossain; Senior Vice President, Clinical and Regulatory Affairs Alexandra D.J. Mancini; SVP, Corporate Strategy & Investor Relations Chris Bogart; and Chief Financial Officer Jeff Charpentier, as well as Chief Medical Officer Dr. Ado Muhammed, MD, DPM, MFPM.

Muhammed, in particular, has an extensive history in the pharmaceutical industry, having previously served as an executive of GW Pharmaceuticals, a global leader in the development of cannabinoid-based medicines. During his time as Associate Medical Director of that company, Muhammed played an instrumental role in the development and FDA approval of one of the first cannabis drugs. This GW Pharmaceuticals development program coincided with a sharp rise in share price from less than $9 in 2013 to more than $129 today, with the company’s current market value totaling more than $2.9 billion. Disclaimer

InMed Pharmaceuticals, Inc. Company Blog

InMed Pharmaceuticals, Inc. News:

Biosynthesis Could Reduce Regulatory Hurdles for Cannabis Researchers -- CFN Media

InMed Announces Appointment of Creative Capital Media

InMed Announces Publication in European Journal of Pain


The QualityStocks Daily Newsletter would like to spotlight ABcann Global (ABCCF). Today, ABcann Global closed trading at $0.6967, up 1.86%, on 196,124 volume with 128 trades. The stock’s average daily volume over the past 60 days is 86,632 and its 52-week low/high is $0.6171/$0.90.

ABcann Global Corporation (TSX-V:ABCN) ("ABcann" or the "Company") is pleased to announce the appointment of Barry Fishman as Chief Executive Officer of the Company, effective October 1, 2017. Mr. Fishman has almost 20 years of experience as a business leader, most recently as CEO of international specialty pharmaceutical company Merus Labs (TSX:MSL) (NASDAQ:MSLI). Under his leadership, sales and EBITDA grew at a compound annual growth rate above 50%, culminating in the acquisition of Merus by Norgine B.V. in July, 2017 for approximately $342 million. He also has several years of experience serving as a director of public companies in the cannabis sector.

ABcann Global (TSX.V: ABCN) (OTCQB: ABCCF) ABcann Medicinals, Inc. is a globally licensed, cost efficient producer of premium quality organic standardized medicinal cannabis. One of the earliest licensed Canadian medical marijuana producers under Canada's federally-controlled Access to Cannabis for Medical Purposes Regulations (ACMPR), ABcann has five years of operating experience in the burgeoning medical marijuana space. The company currently owns and operates a fully functioning 14,500 square foot facility in Napanee, Ontario. Additionally, ABcann owns 65 acres of real estate with proper zoning and existing infrastructure in place to support the construction of another production facility of up to one million square feet.

In a November 2016 report, market research firm Canaccord Genuity Group forecasted that the medical marijuana market in Canada could see sales in excess of $8 billion by 2024, creating a sizable opportunity for the country's licensed producers (LPs). The research firm also noted that the "rigorous process of becoming a licensed producer of cannabis in Canada imposes significant barriers to entry and there will be a shortfall of supply in a legalized market in the short-term." This market barrier serves as a strategic advantage for ABcann as it prepares for its highly-anticipated IPO, which is currently scheduled for April 2017.

Canaccord's synopsis of the Canadian cannabis industry is supported by recent market activity, as companies sporting one of the illustrious Canadian government licenses for medicinal production have recorded strong growth following IPO. Canopy Growth (OTC: TWMJ), one of the largest fully-licensed Canadian marijuana growers, saw share prices skyrocket by more than 700 percent in the months following its initial offering. Aphria Inc. (OTC: APHQF), another licensed grower, climbed by more than 900 percent following its IPO. Other companies that have recorded huge growth since going public include Aurora Cannabis (OTC: ACBFF), climbing nearly 900 percent, and SupremePharma (OTC: SPRWF), which soared more than 1,300 percent.

With these market trends in mind, ABcann's impending IPO is one that prospective investors in the marijuana sector will want to explore. Recalls from some of the biggest players in the Canadian cannabis industry have highlighted the considerable learning curve that LPs face in today's market, which makes ABcann's proven track record in the market all the more noteworthy. The company has built a reputation over the years for its best-in-class standardized approach to growing cannabis, including the thoughtful omission of pesticides and a computer monitored growing technique that allows ABcann to minimize the risks of variance in its yields and ensure the creation of consistently high-quality products.

This technique, which the company calls the ABcann Advantage, has helped it record a customer retention rate of 94.7 percent alongside 30 percent month-over-month customer growth. When combined with ABcann's current yield rate, which it has measured at roughly 100 percent greater than the industry average, the company has constructed a strong foundation upon which to build a sizable presence in the global cannabis industry. This global growth potential is illustrated by ABcann's partnership with Israel's Syqe Medical, producer of the world's first selective-dose pharmaceutical grade medicinal plant inhaler. After visiting the company's production facility, Perry Davidson, founder of Syqe Medical, noted that ABcann's production technologies put it "in a class with the best in the world" in its ability to produce standardized pharmaceutical grade cannabis.

ABcann's entry into the public sector is being guided by a seasoned management team, board of directors and advisory board that feature well over a century of combined industry experience. Ken Clement, the company' founder and executive chairman, has been the key component and driving force behind ABcann's development since its inception. His vision of standardized production and dosage sets ABcann apart in the medical cannabis sector. Clement is joined on the company's management team by CEO Aaron Keay. Keay brings more than a decade of capital markets experience to ABcann, having played a role in raising approximately $250 million for public and private market issuers.

Notably, ABcann also has access to the 'Father of Cannabis Research', Raphael Mechoulam, PhD, through its board of advisors. An organic chemist and professor of medicinal chemistry at the Hebrew University of Jerusalem, Mechoulam was the first scientist to isolate both cannabidiol (CBD) and tetrahydrocannabinol (THC), and he has received more than 25 prestigious academic awards, including the Rothschild Prize in Chemical Sciences and Physical Sciences in 2012.

With more than 65 acres of growth capacity, a healthy cash balance to fund upcoming construction efforts, steady sales growth, industry-leading yield rates and an established operations team in place, ABcann is well-positioned to compete in the rapidly-expanding Canadian medicinal cannabis industry. These factors, along with the company's ongoing global expansion into the European, Australian and Israeli markets, show why ABcann Medicinals' upcoming public offering fits the bill as "Canada's Next Medical Marijuana IPO." Disclaimer

ABcann Global Blog

ABcann Global News:

ABcann Global Appoints Barry Fishman as Chief Executive Officer

ABcann Releases High Level CBD Product and Launches Initial Oils Strategy

NetworkNewsWire Announces Publication Discussing Canadian Cannabis Investment Options

Singlepoint, Inc. (SING)

The QualityStocks Daily Newsletter would like to spotlight Singlepoint, Inc. (SING). Today, Singlepoint, Inc. closed trading at $0.07414, up 2.97%, on 11,014,956 volume with 714 trades. The stock’s average daily volume over the past 60 days is 21,994,154, and its 52-week low/high is $0.0075/$0.415.

NetworkNewsWire ("NNW"), a multifaceted financial news and publishing company, today announces the publication of an editorial featuring SinglePoint, Inc. (OTC: SING), a client of NNW focused on strengthening its position in the marijuana industry through the acquisition of, or investment in, small to mid-sized cannabis companies. The publication, titled, "Cannabis Industry Leaders Drive Growth with Acquisition Strategies and Territorial Expansion," discusses how innovative companies are growing alongside the expanding cannabis sector. To view the full publication, visit: https://www.networknewswire.com/cannabis-industry-leaders-drive-growth-acquisition-strategies-territorial-expansion/

Singlepoint, Inc. (SING) has grown from a full-service mobile technology provider to a publicly-traded holding company. Through diversification into horizontal markets, SinglePoint is building its portfolio by acquiring an interest in undervalued subsidiaries, thereby providing a rich, diversified holding base.

SinglePoint's approach is to first research and identify acquisition opportunities in which it can take an active and influential role among existing leadership to provide enhanced strategy and direction. Target companies are undervalued, cash-flow positive, with high potential and verified assets. SinglePoint acquires and takes controlling interest of successful candidate companies.

SinglePoint recently signed a Letter of Intent to acquire an interest in Jacksam Corp., dba Convectium, a profitable California-based provider of equipment, branding, and packaging solutions for the cannabis industry. Convectium has developed the world's first cartridge and vape pen oil filling machine for wholesale distribution to dispensaries. The 710Shark and 710Seal systems can fill and package over 100 cartridges or disposable vape pens in 30 seconds and are sold to dispensaries through its EquipCanna.com brand. The company also operates a consumer brand that includes BlackoutX and HazeSticks and reaches customers in over 52 countries.

Additionally, SinglePoint has raised more than $300,000 and has signed a Letter of Intent to secure an additional $1 million in funding. The move provides management with ample capital to execute its business plan, while avoiding debt repayments that can eat into cash flow and reduce flexibility over time. It's also a rare development for a development-stage company in the cannabis industry.

Guided by a visionary leadership team with extensive experience in technology, engineering, marketing and raising capital, SinglePoint continues to explore high-potential acquisition opportunities to grow and diversify its current holding base. The company also plans to uplist to the OTCQB and become a fully reporting company during the current fiscal year.

The company has engaged Milost Advisors to pursue acquisitions and financing facilities toward funding acquisitions, as well as to provide working capital. Milost Advisors will assist SinglePoint in the acquisition of undervalued companies with annual revenues of at least $50 million, and has already identified potential acquisition targets for the company to consider. Disclaimer

Singlepoint, Inc. Company Blog

Singlepoint, Inc. News:

NetworkNewsWire Announces Publication Highlighting Key Players in Big Pharma M&A

SinglePoint Completes Acquisition of Dr. FeelGood, a Profitable Cannabis Distribution Company

NetworkNewsWire Announces Publication Discussing the Application of Bitcoin to the Cannabis Sector

Lexaria Bioscience Corp. (CSE:LXX) (OTCQB:LXRP)

The QualityStocks Daily Newsletter would like to spotlight Lexaria Bioscience Corp. (LXRP). Today, Lexaria Bioscience Corp. closed trading at $0.36, off by 8.63%, on 163,280 volume with 51 trades. The stock’s average daily volume over the past 60 days is 78,948 and its 52-week low/high is $0.11/$0.699.

NetworkNewsWire ("NNW"), a multifaceted financial news and publishing company, today announces the publication of an editorial featuring Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP), a client of NNW that develops and out-licenses its proprietary technology for improved taste, rapidity, and delivery of bioactive compounds, including cannabinoids. The publication is titled, "Landmark M&A Deals Continue to Shape Big Pharma." It discusses the perpetual merger and acquisition activity guiding the pharmaceutical industry today. To view the full publication, visit: https://www.networknewswire.com/landmark-ma-deals-continue-shape-big-pharma/

Lexaria Bioscience Corp. (LXRP) has developed and out-licenses its proprietary technology for improved taste, rapidity, and delivery of bioactive compounds, including cannabinoids. Though boasting a wide range of health benefits, cannabinoids are traditionally poorly absorbed by the body's gastrointestinal tract. To achieve higher effectiveness, consumers usually default to smoking. Lexaria provides a superior administration method by delivering hemp oil ingredients – or through locally licensed partners, cannabis oil ingredients – through a patented process within food products.

The key differentiator between Lexaria's products and others on the market is the company's disruptive technology proven to enhance the absorption of orally ingested cannabinoids while improving the "unusual" taste of cannabinoids and allowing for lower overall dosing with higher efficacy. Lexaria is primarily a B2B enterprise, and is in licensing discussions or has existing agreements with companies in Canada, the largest-market states in the USA, and internationally. Lexaria has also developed its own brands partly for demonstration purposes, utilizing its patented technology to infuse hemp oil ingredients within lipids in popular foods. These brands include ViPova™, Lexaria Energy Foods, and TurboCBD™.

In 2015, Lexaria commissioned an independent, third-party lab to test its technology under carefully monitored in vitro conditions. Results showed that the company's technological process and lipid formulation both improve intestinal absorption as much as 500%. Additional follow-up studies in human volunteers suggested that Lexaria's processed, lipid-infused tea may be more effective in an actual gastrointestinal system than in an in vitro simulation with results indicating as much as a 1,000% increase in overall absorption.

Lexaria also has an R&D partnership with the Canadian government's National Research Council. That R&D is expected to characterize molecular bond formation theorized to occur with Lexaria's unique technology between the lipid delivery agents and the bioactive substances it processes and combines. Results from this R&D are expected to support accelerating B2B relationships – not just in the cannabis industry, but also to support new B2B business relationships in the fields of vitamins, NSAIDs, and nicotine delivery. All of these sectors expected to offer additional future growth potential.

Aside from testing, a critical component of Lexaria Bioscience's business model is a strong intellectual property portfolio that utilizes the most commonly used food processing techniques. As of 2017, the company's patent portfolio includes 19 patent applications filed and pending in more than 40 countries around the world. The most recent patent applications expand Lexaria's lipophilic food and beverage composition claims to include the processing of cannabinoids, vitamins, NSAIDs and nicotine in many of the world's most commonly used food processing ingredients. Lexaria is expecting additional new patent awards both in the USA and internationally in 2017 and 2018.

Royalties play a vital role in Lexaria's revenue-generating business model. The company out-licenses its technology (royalty) to third party partners, and has several deals signed and/or pending. The company's growth initiatives are guided by a management team headed by CEO Chris Bunka, a serial entrepreneur who has raised more than $50 million in working capital for the companies he has led over the course of his career. He is supported by a team of professionals with extensive experience in pharmaceutical and bioscience sectors, invention, toxicology, consumer goods, and other relevant skillsets. Disclaimer

Lexaria Bioscience Corp. Blog

Lexaria Bioscience Corp. News:

NetworkNewsWire Announces Publication Highlighting Key Players in Big Pharma M&A

University of British Columbia to Perform Clinical Study on the Cardiovascular and Cognitive Health Effects of Lexaria's TurboCBD

NetworkNewsWire Announces Publication Highlighting Companies Taking Innovative Strides in the Tobacco Industry

AppSwarm, Inc. (SWRM)

The QualityStocks Daily Newsletter would like to spotlight AppSwarm, Inc. (SWRM). Today, AppSwarm, Inc. closed trading at $0.01, up 16.28%, on 72,501 volume with 5 trades. The stock’s average daily volume over the past 60 days is 215,291 and its 52-week low/high is $0.002/$0.13.

AppSwarm, Inc. (SWRM) is a technology development and incubation acceleration company that partners up with developers through joint ventures, royalty agreements, marketing partnerships, and outright purchase agreements. Focusing on the ever-growing mobile applications market, the company provides all the resources needed for engagement, retention, virality and monetization.

The global games market generated approximately $100 billion in revenues in 2016, but large global game companies have made it extremely difficult for smaller developers to achieve success in the marketplace. As a result, many great ideas aren't monetized. AppSwarm solves this problem by providing the funding and critical business expertise needed to successfully launch and market new applications.

Business applications is another area of focus for the company. Targeting small to medium sized businesses, AppSwarm will be developing and acquiring mobile application tools and platforms that increase productivity and security via data encryption, cloud storage, content management and delivery, digital payments, automation, and customer loyalty marketing solutions. Recent acquisitions made so far represent only a small example of future planned initiatives to develop and market tools for the business community.

Regardless of the target market, AppSwarm can help developers accelerate the success of their app through funding, technology and marketing expertise, as well as a unique eco system that accelerates user acquisition. The company is able to assist at any state of development with completion of concept, market analysis, business and financial management, direct sales and marketing, social game development to ensure correct product application and expedient deployment with cost efficiency.

Ron Brewer, CEO of the company, has accumulated extensive leadership in the technology sector and brings valuable knowledge gained as a Director of Southbridge Advisory Group for nearly 20 years. Ron's C-level experience includes merger & acquisition and post-acquisition turnaround in both the private and small-cap public sector. John Rabbit, director of finance, is a seasoned business veteran that has worked with Fortune 500 firms and served in CEO, COO and CFO positions for firms ranking from $5 million to $300 million in annual revenues. John was directly involved in numerous acquisitions and served in executive capacities for several multinational subsidiaries.

With a well-suited management team, multiple synergistic revenue streams, and diversified growth strategy, AppSwarm is well positioned in a steadily growing industry with countless opportunities for capitalization. Disclaimer

AppSwarm, Inc. Blog

AppSwarm, Inc. News:

AppSwarm, Inc. (SWRM) Engages NetworkNewsWire for Corporate Communications Solutions

AppSwarm Announces Acquisition of Multiplatform Games Developer and Publisher MediaPlay and the Creation of Two Divisions of AppSwarm, Inc.

AppSwarm, Inc. (SWRM) Ahead of the Game as It Seeks to Increase Choice for More than 2 Billion Players


Rate Us
Tell us how we're doing!
Click here to begin your review.

Today's Top 3
Investment Newsletters



Trader Power News
(NLNK) +74.58%


(RH) +44.76%


(EGAN) +28.57%

By The Numbers Charts

The QualityStocks Public Company Sponsor News

Featured Sponsor

Daily Sponsors


The QualityStocks By The Numbers Report

Click the chart below to see the full report

About "The QualityStocks Daily"

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market
each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge"
based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?

We Want To bring our subscribers the top movers in an unbiased setting.

“Homework Eliminates Mistakes"

Please never invest in a company anyone profiles unless you do the proper research and due diligence.
QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.
Please consult the QualityStocks Market Basics Section on our site.


About Us     Archives     Blog     Clients     Disclaimer     Market Basics    Partners      Quotes & News     Video     Contact Us

twitter icon facebook icon

QualityStocks Logo

Copyright © 2006 - 2012. QualityStocks 3370 N. Hayden Rd., Suite 123-591, Scottsdale, AZ 85251